TL;DR
This study uses RNA sequencing to reveal how high blood pressure (hypertension) alters gene expression in the left atrium of rats, even before structural damage occurs. It identifies key molecular pathways involved in atrial remodeling and shows how two common blood pressure medications (ARB and ARNI) differentially affect these changes, offering insights into preventing atrial fibrillation.
What Problem Does This Paper Address?
Atrial fibrillation (AF), a common heart rhythm disorder, is strongly linked to hypertension. While hypertension is known to cause structural changes in the heart, including the left atrium (leading to enlargement and fibrosis), the precise molecular mechanisms by which hypertension initially impacts the left atrium's gene expression profile remain unclear. Understanding these early transcriptional changes is crucial for developing preventative strategies against AF in hypertensive individuals. This paper aims to fill this knowledge gap by investigating the transcriptomic landscape of the left atrium in spontaneously hypertensive rats (SHRs) at an early stage of the disease, and to explore how common antihypertensive treatments might reverse these changes.
Methods
The researchers employed a multi-pronged approach:
- RNA Sequencing (RNA-seq): This is the core technique used to comprehensively analyze the gene expression profiles of the left atrium. They compared:
- Normotensive Wistar-Kyoto (WKY) rats (control group).
- Spontaneously Hypertensive Rats (SHRs).
- SHRs treated with an Angiotensin Receptor Blocker (ARB).
- SHRs treated with an Angiotensin Receptor-Neprilysin Inhibitor (ARNI).
- Bioinformatics Analysis: This was critical for making sense of the vast RNA-seq data. Key analyses included:
- Differential Gene Expression (DEG) analysis: Identifying genes with significantly different expression levels between groups.
- Gene Ontology (GO) analysis: Categorizing DEGs based on their biological processes, molecular functions, and cellular components.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis: Identifying enriched biological pathways that are affected by hypertension and treatments.
- Key Driver Analysis (KDA): Identifying central regulatory genes that might be orchestrating the observed transcriptional changes.
- Principal Component Analysis (PCA): Visualizing the overall transcriptomic differences between the groups.
- Heatmaps: Visualizing the expression patterns of dysregulated genes across the different groups.
- Histological Analysis: Hematoxylin and eosin (H&E) and Masson's trichrome staining were used to assess structural changes like inflammation, necrosis, and fibrosis in the atrial tissue.
- Immunohistochemistry: Used to specifically examine the expression of TGF-β, a key protein implicated in fibrosis.
Datasets
The study generated RNA-seq data from the left atrial tissues of four groups of rats: WKY, SHR, ARB-treated SHR, and ARNI-treated SHR. This data has been uploaded to the Gene Expression Omnibus (GEO) database and can be accessed via accession number GSE207283.
Key Insights and Ideas
- Early Transcriptional Changes Precede Structural Damage: The study found significant differences in gene expression in the left atrium of SHRs compared to WKY rats, even though histological analysis showed minimal apparent structural damage (inflammation or fibrosis) at this early stage. This highlights that molecular alterations are occurring before visible structural remodeling.
- Hypertension Orchestrates Atrial Remodeling Pathways: The differentially expressed genes (DEGs) in SHRs were enriched in pathways related to atrial fibrosis, inflammation, electrical remodeling, and cardiac metabolism. This suggests that hypertension broadly impacts multiple aspects of atrial health.
- Metabolism is a Common Target for Antihypertensive Drugs: Both ARB and ARNI treatments led to changes in genes related to cardiac metabolism. This points to metabolic dysregulation as a key factor in hypertension-induced atrial remodeling and a common target for therapeutic intervention.
- ARNI Has Distinct Effects Beyond Metabolism: While both drugs affected metabolic pathways, ARNI treatment specifically enriched transcripts related to the cyclic guanosine monophosphate-protein kinase G (cGMP-PKG) signaling pathway, suggesting a unique mechanism of action compared to ARB.
- TGF-β Pathway is Upregulated in Hypertension: Immunohistochemistry confirmed that TGF-β expression was higher in SHRs, aligning with the transcriptomic data and reinforcing its role in hypertension-induced atrial fibrosis.
Key Results
- 1,558 Differentially Expressed Genes (DEGs): Found between WKY and SHR groups, with 873 upregulated and 685 downregulated.
- Histology: No significant differences in necrosis or inflammatory infiltration were observed among the groups. Masson's trichrome staining showed no significant differences in mean area density of collagen fibers, though a slight elevation was noted in SHRs.
- GO and KEGG Enrichment: Upregulated genes in SHRs were enriched in pathways like TGF-β signaling, calcium signaling, and MAPK signaling. Downregulated genes were linked to fatty acid metabolism, PPAR signaling, and PI3K-Akt signaling.
- Key Driver Genes: 15 key driver genes were identified, many involved in cardiac metabolism (e.g., fatty acid metabolism, PPAR signaling).
- Hub Genes: Genes like Hadha, Hadhb, and Eci2, involved in fatty acid metabolism, were identified as top hub genes.
- Treatment Effects: ARB treatment primarily affected ribosome, proteasome, oxidative phosphorylation, and amino acid biosynthesis pathways. ARNI treatment impacted citrate cycle, AMPK signaling, fatty acid elongation, and PPAR signaling pathways.
Limitations and Future Work
- Early Stage Focus: The study focused on the early stage of hypertension. Further research is needed to understand how these transcriptional changes evolve over time and in more advanced stages of the disease.
- In Vivo Confirmation: While the study provides strong transcriptomic evidence, further in vivo and in vitro experiments are suggested to confirm the hypothesized mechanisms, particularly regarding the ARNI's effect on the cGMP-PKG signaling pathway.
- Translational Relevance: While using a rat model, the findings provide a foundation for investigating similar mechanisms in human hypertensive patients and developing targeted therapies.
- Drug Mechanisms: The study highlights distinct pathways affected by ARB and ARNI. Future work could delve deeper into the specific molecular interactions and downstream effects of these drugs in reversing atrial remodeling.
Summary updated